Objectives-Patients with obesity and diabetes mellitus have increased risk of cardiovascular disease. A major cause is an atherogenic dyslipidemia related primarily to elevated plasma concentrations of triglyceride-rich lipoproteins. The aim of this study was to clarify determinants of plasma triglyceride concentration. We focused on factors that predict the kinetics of very-low density lipoprotein 1 (VLDL 1 ) triglycerides. Approach and Results-A multicenter study using dual stable isotopes (deuterated leucine and glycerol) and multicompartmental modeling was performed to elucidate the kinetics of triglycerides and apoB in VLDL 1 in 46 subjects with abdominal obesity and additional cardiometabolic risk factors. Results showed that plasma triglyceride concentrations were dependent on both the secretion rate (r=0.44, P<0.01; r=0.45, P<0.01) and fractional catabolism (r=0.49, P<0.001; r=0.55, P<0.001) of VLDL 1 -triglycerides and VLDL 1 -apoB. Liver fat mass was independently and directly associated with secretion rates of VLDL 1 -triglycerides (r=0.56, P<0.001) and VLDL 1 -apoB (r=0.53, P<0.001).
C ardiovascular disease remains the leading cause of morbidity and mortality, despite recent significant advances in management strategies to lessen cardiovascular disease risk factors. 1 A major cause is an atherogenic dyslipidemia related primarily to elevated plasma concentrations of triglyceriderich lipoproteins (TRLs).
See accompanying editorial on page 2076
Elevation of very-low density lipoprotein 1 (VLDL 1 )triglycerides is the major determinant of plasma triglyceride concentration in normal subjects and insulin-resistant individuals. 2 The plasma concentration of VLDL 1 is a function of hepatic secretion and the clearance of triglyceride-rich remnant particles from the circulation. 3, 4 We have earlier shown that liver fat and hyperglycemia are associated with increased secretion of VLDL 1 particles from the liver and that suppression of VLDL 1 secretion by insulin is impaired in subjects with increased hepatic fat content leading to oversecretion of VLDL 1 particles. 5, 6 However, the mechanism(s) for the disturbed removal of VLDL 1 -triglycerides are less clarified.
The enzyme lipoprotein lipase (LPL) has a critical role in hydrolyzing plasma triglycerides and in hepatic uptake of remnant particles. 7 On production by the underlying parenchymal cells, LPL is transported and attached to the capillary endothelium by the protein GPIHBP1. 8 The critical role of LPL for the hepatic removal of remnant particles originating from TRLs, and for the conversion of large VLDL 1 particles into smaller VLDL 2 particles and intermediate-density lipoprotein, 9 was recently illustrated in studies in subjects with LPL gene mutations. 10 Because LPL is rate limiting for plasma triglyceride clearance and tissue uptake of fatty acids, the activity of LPL is carefully controlled via multiple mechanisms at both the transcriptional and post-translational level. 7, 11 Whereas LPL is predominantly a triglyceride lipase, hepatic lipase is both a phospholipase and a triglyceride lipase which plays an important role in the conversion of VLDL to low-density lipoprotein. 12 Insulin is a major regulator of LPL synthesis and activity. 11 Several apolipoproteins including the apoC family, apoA5, apoE, and angiopoietin-like 4 (Angptl4) are also known to modulate LPL activity and action. 11, [13] [14] [15] [16] [17] [18] In particular, apoC-III has emerged as a clinically important predictor of hypertriglyceridemia because it inhibits LPL-catalyzed hydrolysis of TRLs 19, 20 and attenuates the uptake of TRL remnants by the liver. 21, 22 In addition, also the cholesterol ester transfer protein (CETP) has been shown to affect TRL composition and metabolism. 23, 24 Thus, the prevailing idea is that the concerted actions of lipolytic enzymes, apolipoproteins, and transfer proteins determine TRL metabolism and thus plasma triglyceride concentrations. However, there is a clear lack of data on the interplay between these key players and VLDL 1 -triglyceride kinetics.
In this study, we performed lipoprotein kinetic studies in 46 middle-aged men and women with abdominal obesity and additional cardiometabolic risk factors to clarify determinants of plasma triglyceride concentration. Specifically, we focused on factors associated with VLDL 1 -triglyceride kinetics.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Characteristics of the Abdominally Obese Population
The clinical and biochemical characteristics of 46 middleaged men (n=37) and women (n=9) are shown in Table 1 . The subjects were abdominally obese, with a mean body mass index of 32.3±3.3, large waist circumference of 108.5±8.5 cm, and high insulin resistance (mean HOMA-IR [homeostasis model assessment-insulin resistance index] value of 3.2±2.0). In addition, the subjects exhibited the typical dyslipidemia of the metabolic syndrome with high plasma triglycerides and low high-density lipoprotein cholesterol. Table 2 presents the kinetic data for triglycerides and apoB100 in VLDL 1 particles, and Table I Table 2) .
The kinetic parameters describe secretion of lipoproteins and triglycerides from the liver (VLDL 1 -triglyceride and VLDL 1 -apoB secretion rates) and removal of triglycerides from VLDL 1 .The triglycerides are removed from VLDL 1 by 3 pathways: particles transferred from VLDL 1 to VLDL 2 because of lipolysis (characterized by the VLDL 1 fractional transfer rate [FTR]), particles removed by direct catabolism (ie, VLDL 1 particle uptake by cells), and triglyceride removal by hydrolysis. The latter 2 are combined into the fractional direct catabolic rate (FDCR). Total catabolism of VLDL 1 is summarized as fractional catabolic rate (FCR). Subject characteristics are given as mean±SD for normally distributed variables and as median (minimum-maximum) for non-normally distributed variables. BMI indicates body mass index; CETP, cholesterol transfer protein; F, female; HDL, high-density lipoprotein; HL, hepatic lipase; HOMA-IR, homeostasis model assessment-insulin resistance index; LDL, low-density lipoprotein; LPL, lipoprotein lipase; M, male; PLTP, phospholipid transfer protein; and RBP4, retinol binding protein 4. October 2015 Table 2 shows the correlations between kinetic parameters of triglycerides and apoB in VLDL 1 . The catabolism of VLDL 1triglycerides, calculated as the FCR, did not correlated with any of the conventional cardiometabolic risk factors (Table  II in the online-only Data Supplement) but was strongly correlated with plasma apoC-III concentration. As expected, apoC-III concentration was tightly associated with plasma triglyceride concentration (r=0.84, P<0.001; Table II in the online-only Data Supplement).
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VLDL 1 -Triglyceride Kinetics Are Linked to apoC-III but Not to LPL or Hepatic Lipase
In contrast, neither activity nor mass of postheparin LPL which is regulated by apoC-III correlated with the plasma triglyceride concentration or VLDL 1 -triglyceride kinetics ( Figure 1A and 1B). Furthermore, hepatic lipase activity did not correlate with VLDL 1 -triglyceride catabolism (Table 3 ). However, LPL mass correlated with VLDL 2triglyceride and apoB FCR ( Table III in 
the online-only Data Supplement).
ApoC-II correlated with apoC-III (Table II in the onlineonly Data Supplement) but did not correlate with VLDL 1triglyceride kinetics (Table 3) . ApoE correlated strongly with apoCII, apoCIII, and plasma triglycerides ( Table II in the  online-only Data Supplement) . Surprisingly, apoA5 did not show a correlation with plasma triglyceride concentration or VLDL 1 particle kinetics ( Table 3 ; Table II in the online-only Data Supplement). In a stepwise multivariable regression, which included variables with univariable correlation P<0.10, only apoC-III remained an independent predictor of VLDL 1triglyceride FCR and apoC-III, and hepatic lipase were independent predictors of VLDL 1 -apoB FCR (Table IVC and IVD in the online-only Data Supplement). ApoC-III and apoE also correlated with the VLDL 2 -triglyceride FCR ( Table III in 
Indices of VLDL 1 -Triglyceride Catabolism Are Stronger Predictors of Plasma Triglycerides Than Secretion Rate
The concentration of triglycerides in plasma is the balance between secretion and removal of VLDL 1 -triglycerides. Thus, the concentration of plasma triglycerides can be illustrated as the consequence of a Synthesis pathway and a Clearance pathway ( Figure 2 ). VLDL 1 -triglyceride secretion was strongly correlated (P<0.01) with liver fat content, total fat mass and body fat, and glucose (see Table 2 for r and P values). In stepwise multivariable regression, only liver fat content (P<0.01) and total fat mass (P<0.05) were independent predictors of VLDL 1 -triglyceride secretion (adjusted r 2 =0.34; Table IVA in the online-only Data Supplement). For VLDL 1 -apoB, only liver fat content (P<0.001) was an independent predictor of secretion (adjusted r 2 =0.25; Table IVB in the online-only Data Supplement). Secretion rates explained 19% to 20% of the variation in plasma triglyceride concentrations in the study subjects (ie, the r 2 value of the correlation value for VLDL 1 -triglyceride secretion presented in Table 3 ). Importantly, the kinetic parameters in the Clearance pathway were stronger predictors of plasma triglycerides than secretion. The FCR of VLDL 1 -triglycerides explained 24% of the variation in plasma triglycerides (Table 3) , whereas the fractional transfer rate explained 37% ( Table 3 ). The corresponding percentages for VLDL 1 -apoB were 30% and 46% (Table 3 ). In addition, direct clearance (ie, removal of whole particles and removal of lipids by hydrolysis of VLDL 1 -triglycerides) explained only 9% (Table 3) .
In a multivariable regression model, VLDL 1 -triglyceride kinetics explained 76% of the variation in the total plasma triglycerides ( 
Discussion
We performed a large kinetic study in subjects with abdominal obesity and additional cardiometabolic risk factors to clarify the predictors of the kinetics of VLDL 1 -triglycerides. Our results show that kinetic parameters of VLDL 1 -triglyceride Kinetic parameters are given as mean±SD (minimum-maximum) for normally distributed variables and as median (minimum-maximum) for nonnormally distributed variables. Triglyceride pool (mg/dL) pool can be converted to concentration (mmol/L) by multiplying with 0.0113, and apoB100 pool (mg/dL) can be converted to concentration (g/L) by multiplying with 0.01. FCR indicates fractional catabolic rate; FDCR, fractional direct catabolic rate, FTR, fractional transfer rate; SR, secretion rate; and VLDL 1 , very-low density lipoprotein 1. catabolism are stronger determinants of the plasma triglyceride concentration than indices for the increased secretion of VLDL 1 particles. The catabolism of VLDL 1 -triglycerides did not correlate with any of the conventional cardiometabolic risk factors but showed a strong correlation with the plasma concentration of apoC-III and apoE. Their plasma concentrations were also strongly and directly associated with the plasma triglyceride concentration.
The prevailing notion about the function of apoC-III is that it is an antagonist to apoC-II and apoE, impairing intravascular lipolysis by LPL and liver clearance of apoB lipoproteins. This concept is supported by in vitro evidence showing that apoC-III noncompetitively inhibits LPL 25, 26 and by the markedly accelerated catabolism of TRLs in human subjects with a genetic deficiency of apoC-III. 19 Also, apoC-III strongly inhibits the in vitro binding of apoB lipoproteins to the hepatic low-density lipoprotein receptor. 22 Recently, loss-of-function mutations in apoC-III were shown to associate with reductions in the risk of ischemic vascular disease and ischemic heart disease in the general population. 27, 28 Thus, apoC-III emerges as an important drug target for reducing residual cardiovascular risk. 29 Indeed, inhibition of apoC-III by antisense oligonucleotides has recently been shown to reduce plasma levels of apoC-III and triglycerides in humans. 30 In addition, pharmacological intervention has been shown to influence the apoCIII levels in parallel with decreased plasma triglycerides. [31] [32] [33] However, the molecular mechanisms for how apoC-III induces hypertriglyceridemia are complex and further research is required. 34 For example, in a Phase 2 study, 3 LPL-deficient patients were treated with an inhibitor of APOC3 messenger RNA. After 13 weeks, plasma apoC-III levels were reduced by 71% to 90% and triglyceride levels by 56% to 86%. 35 These data support the role of apoC-III as a key regulator of LPL-independent pathways of triglyceride metabolism. 36, 37 Consistent with this result, kinetic studies indicate that VLDL with apoC-III show faster, not slower, lipolytic conversion rates to smaller lipoproteins than particles without it. 38 Our results also showed that the plasma concentration of apoC-II correlated with the plasma concentration of apoC-III in line with our previous findings. 2 However, it did not correlate with turnover of VLDL 1 -triglycerides. Interestingly, the lipoprotein concentrations of apoC-II and apoC-III are independently regulated in VLDL particles. This independence leads to varying ratios of the 2 apolipoproteins. This is important because the apoCII/apoCIII ratio may be a critical factor in the regulation of lipolysis of VLDL particles. 31, 39 ApoE, a major ligand for the low-density lipoprotein receptor, is considered to promote hepatic clearance of chylomicron and VLDL remnants. 40 However, apoE correlated strongly with apoCII, apoCIII, and plasma triglycerides. An explanation for this might be that apoC-III has been proposed to override the positive effects of apoE on clearance of TLRs, when both are present. 41 ApoA5 is proposed to play an important role in regulating the plasma triglyceride levels, but it did not correlate with plasma triglycerides or kinetics of VLDL 1 . This data do not support a role of plasma apoA5 in regulating VLDL 1 kinetics and is in agreement with results by Chan et al. 42 An unexpected finding in our study was that neither LPL activity nor mass correlated with VLDL 1 -triglyceride clearance. These results may indicate that either LPL is not regulating the rate of lipolysis or that LPL activity measurements do not adequately reflect the in vivo rate of lipolysis. The measurements were performed after injection of heparin, a procedure that releases LPL from endothelium. 43, 44 However, the physiopathological relevance of this postheparin lipolysis assay has been questioned because it has never been demonstrated that the bulk of endothelium-bound LPL is physiologically active. 45 It has been recently shown that a small part of LPL is associated to circulating lipoproteins in nonheparinized plasma raising the possibility that the lipolysis mediated by this circulating LPL might reflect the overall LPL-dependent triglyceride hydrolysis in plasma. [45] [46] [47] [48] [49] It has further been proposed that LPL bound to VLDL particles is not only responsible for hydrolyzing apoB lipoproteins at the endothelium but also facilitating receptor-mediated uptake during circulation. 50 The protocol for the analysis of the postheparin LPL activity was carefully standardized. This is critical because lipolysis and clearance of TRLs are enhanced early after heparin injection. Later, when heparin and lipase concentrations have decreased, both lipolysis and particle clearance are slower than in controls. Indeed, heparin treatment in humans leads to delayed clearance of chylomicron triglycerides and particles because of a temporary depletion of endothelial LPL with impaired lipolysis of TRLS. 51 We neither found any correlation between adiponectin and VLDL kinetics, despite the fact that plasma adiponectin has been proposed to be an important regulator of basal VLDLtriglyceride secretion and catabolism. [52] [53] [54] The reason for this difference is unclear.
This study represents the largest kinetic study performed to date, but it has some limitations. Our results are based on correlational analyses and need to be formally tested in intervention studies that specifically target apoB and apoC-III secretion. Furthermore, the study subjects are extensively phenotyped obese whites. Thus, the results may not apply to other patient groups. In addition, it could be hypothesized that exclusion of hypertriglyceridemic individuals with plasma triglyceride >4.5 mmol/L may have affected the relationship between LPL mass or activity and VLDL kinetic parameters. We also combined women (n=9) and men (n=37) in the analyses, but the results were similar when men only were analyzed (Table V in the online-only Data Supplement). To improve the precision of the kinetic estimates, we used a combined model in which the triglyceride and apoB kinetics were estimated together. For comparison, we also modeled the triglyceride and apoB kinetics independently and the 2 approaches showed good agreement ( Figure II in the online-only Data Supplement). This result is in line with data by Ramakrishnan et al 55 showing that triglycerides and apoB kinetics are identical along the VLDL delipidation.
In conclusion, our results further show that the turnover of VLDL 1 -triglycerides is linked to apoC-III, but not to postheparin LPL activity of LPL mass, and that the VLDL 1 -triglyceride clearance is a stronger determinant of the plasma triglyceride concentration than increased secretion of TRLs. These results recognize apoC-III as a key target for reducing residual cardiovascular risk and question the clinical relevance of measuring postheparin LPL activity except for identifying subjects with LPL deficiency and suspected functional mutations in LPL. Figure 2 . Key parameters linked to very-low density lipoprotein 1 (VLDL 1 )-triglyceride (TG) secretion and catabolism. In a stepwise multivariable regression analysis, only liver fat content (P<0.01) and total fat mass (P<0.05) remained independent predictors of VLDL 1 -TG secretion rate (SR). The plasma concentration of apoC-III was tightly linked with plasma TG and the fractional catabolism of VLDL 1 -TG. Indices of catabolism were stronger predictors of plasma triglycerides than parameters of secretion.
In a multivariable regression model, VLDL 1 -TG kinetics explained 76% of the variation in the total plasma triglycerides ( Table IVE in the online-only Data Supplement). The commonly observed associations between liver fat and fat mass vs plasma TG (dotted lines) are likely secondary and mediated via VLDL 1 SR. Likewise, the direct effect of apoC-III on plasma TG (dotted line) is likely explained by effect(s) of apoC-III beyond lipoprotein lipase-independent pathways of triglyceride metabolism. 36, 37 Despite tremendous success in lowering age-adjusted morbidity and mortality from atherosclerotic cardiovascular disease, the disease has not been eradicated, not even for patients on maximal medical therapy. In particular, subjects with obesity, type 2 diabetes mellitus, and insulin resistance remain at a high risk for cardiovascular disease. A major cause is an atherogenic dyslipidemia, which consists of elevated plasma concentrations of both fasting and postprandial triglyceride-rich lipoproteins, small dense low-density lipoprotein and low high-density lipoprotein cholesterol. The different components of the dyslipidemia are metabolically linked and driven by increased plasma concentration of triglyceride-rich lipoproteins. Thus, the underlying disturbances are hepatic overproduction of large triglyceride-rich VLDL 1 and delayed clearance of triglyceride-rich lipoproteins. The aim of this study, which represents the largest kinetic study performed until date, was to clarify determinants of plasma triglyceride concentration. We focused on factors that predict the kinetics of VLDL 1 (very-low density lipoprotein 1) triglycerides.
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